Nicox SA (OTCMKTS:NICXF – Get Free Report) saw a large growth in short interest in March. As of March 13th, there was short interest totaling 421 shares, a growth of 1,904.8% from the February 26th total of 21 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 0 shares, the short-interest ratio is presently ? days.
Nicox Price Performance
OTCMKTS:NICXF opened at $0.30 on Thursday. Nicox has a 52-week low of $0.25 and a 52-week high of $0.30. The stock’s 50-day simple moving average is $0.30 and its 200 day simple moving average is $0.30.
About Nicox
Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.
The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.
Featured Articles
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
